According to the research report titled ‘Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts’, available with Market Study Report, global blockbuster drugs market is expected to cross the USD 292 billion mark by the year 2025.
 

This research report offers crucial data regarding the major development trends, restraining factors, and other expansion opportunities that are likely to impact the growth rate of this business vertical over the period of 2020-2025. It also compares the past records with the current market trends in a bid to formulate the revenue scale of this industry vertical.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1374385/
 

Apart from this, the document specializes in offering statistical information regarding the market size, volume, and valuation through 2025, while discussing the current and future developments of global blockbuster drugs industry. It also explores top 150 drugs in the market currently.
 

The top drugs analyzed by global blockbuster drugs market report are Relvar/Breo Ellipta, Trajenta/ Jentadueto, Jardiance, Jakafi/Jakavi, Trivicay, Xtandi, Ocrevus, Prolia/Xgeva, Darzalex, Pomalyst/Imnovid, Zepatier, Symbicort, Humalog, Cialis, Trulicity, Cosentyx, Gilenya, Seretide/Advair, Tirumeq, Soliris, Botox, Vitoza, Eylea, Tecfidera, Tagrisso, Enbrel, Xarelto, Invega Sustenna, Zytiga, Stelara, Simponi, Ibrance, Lyrica, Sprycel, Orencia, Eliquis, Opdivo, Perjeta, MabThera/Rituxan, Avastin, Herceptin, Januvia/Janument, Keytruda, Epclusa, Harvoni, Truvada, Genvoya, Revlimid, Imbruvica, and Humira.
 

The document talks about the growth strategies adopted by leading companies such as mergers & acquisitions, collaborations, licensing agreements, partnerships, and innovative product launches.
 

The competitive landscape of global blockbuster drugs market is defined by companies such as Astellas Pharma Inc., Boehringer Ingelheim, Incyte Corp., AstraZeneca plc, Eli Lilly & Co., Novartis AG, GlaxoSmithKline plc, Alexion Pharmaceuticals Inc., Allergan plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bayer Corp., Amgen Inc., Johnson & Johnson, Pfizer, Bristol Myers Squibb, Roche Holdings AG, Merck Group, Gilead Sciences, Inc., Celgene Corporation, and AbbVie Inc. among others.